CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
CAMP4 Therapeutics (Nasdaq: CAMP) will participate in a panel at Chardan’s 10th Annual Healthcare Conference on October 20, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CAMP4 Therapeutics (Nasdaq: CAMP) will participate in a panel at Chardan’s 10th Annual Healthcare Conference on October 20, 2026.
The panel, RNA Medicines: Transcriptome Engineering, runs from 9:15–9:45 a.m. EDT in New York. A webcast will be available through CAMP4’s investor relations website, with a replay archived for 30 days following the conference.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the company will participate in a panel during Chardan’s 10th Annual Healthcare Conference on October 20, 2026. Details below:
Chardan’s 10th Annual Healthcare Conference
| Title | RNA Medicines: Transcriptome Engineering |
| Format | Panel |
| Date and Time | October 20, 2026 | 9:15-9:45 a.m. EDT |
| Location | New York, NY |
| Webcast link | Click Here |
The event will be webcast and can be accessed on the investor relations page of CAMP4’s website at www.investors.camp4tx.com. A replay of the webcast will be archived on the CAMP4 website for 30 days following the conference.
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
Contacts
Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com
Media:
Sofia Bermudez
LifeSci Communications
sbermudez@lifescicomms.com
